Jun 282017
 

By Talent4Boards Team

Talent4Boards - Great Talent builds Great Boards

– FRANCE, Paris – Cellectis (Alternext: ALCLS / NASDAQ:CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells, today announced that it has appointed Rainer Boehm, M.D.=> Read more

Cellectis appoints Dr Rainer Boehm and Herve Hoppenot to its Board of Directors

From:: Cellectis appoints Dr Rainer Boehm and Herve Hoppenot to its Board of Directors

Sorry, the comment form is closed at this time.

%d bloggers like this: